Pfizer's Danuglipron Hits Phase 2b Obesity Endpoint
Decision brief
Answer first · skim in under a minute
Pfizer said danuglipron, its oral GLP-1 receptor agonist, met the primary endpoint in a Phase 2b obesity trial with statistically significant weight loss versus baseline. The result strengthens the case for Danuglipron Phase 3 planning and gives BD and investor teams a fresh benchmark against other oral GLP-1 programs.
Pfizer’s oral GLP-1 candidate danuglipron hit its Phase 2b weight-loss endpoint, but Danuglipron Phase 3 never started for the twice-daily tablet. High dropouts and a later liver-safety review ended the program. Investors should treat the Phase 2b win as a closed chapter, not a late-stage catalyst.
Contents9 sections
Key Takeaways
- Phase 2b (NCT04707313) met the primary body-weight endpoint versus baseline/placebo adjustment.
- Placebo-adjusted mean weight loss was about 8%–13% at 32 weeks and 5%–9.5% at 26 weeks.
- Twice-daily danuglipron will not advance into Phase 3; discontinuation rates exceeded 50%.
- On April 14, 2025, Pfizer discontinued all danuglipron development after a potential drug-induced liver injury case.
What did the Phase 2b obesity trial show?
Pfizer announced topline Phase 2b results for oral danuglipron (PF-06882961) in adults with obesity without type 2 diabetes. The study met its primary endpoint of statistically significant change in body weight.
Placebo-adjusted mean reductions ranged from roughly 8% to 13% at 32 weeks and 5% to 9.5% at 26 weeks across twice-daily doses. Primary source: Pfizer Phase 2b topline release.
Why did Danuglipron Phase 3 plans stop?
Despite the efficacy signal, Pfizer said high rates of gastrointestinal adverse events and discontinuations meant the twice-daily formulation will not advance into Phase 3 studies. Future work briefly shifted to a once-daily formulation before the full stop in 2025.
- Nausea up to 73%
- Vomiting up to 47%
- Diarrhea up to 25%
- Discontinuation >50% on drug vs ~40% placebo
What changed in April 2025?
Pfizer later discontinued development of danuglipron entirely. Dose-optimization studies of once-daily formulations (NCT06567327 and NCT06568731) met pharmacokinetic objectives, but a single asymptomatic participant had potential drug-induced liver injury that resolved after stopping the drug.
After reviewing the full clinical package and regulator input, Pfizer ended the molecule. See Business Wire: danuglipron update (April 14, 2025) and the matching Pfizer update.
How BD teams should read the catalyst now
The Phase 2b hit is real but incomplete as a franchise story. Oral GLP-1 competition moved on while Pfizer redirected obesity R&D. Claims that danuglipron is “heading to Phase 3” are outdated against the company’s own December 2023 and April 2025 notices.
Related context: Pfizer company profile and obesity coverage.
What remains unproven
No Phase 3 efficacy or safety package exists for danuglipron. Placebo-adjusted Phase 2b weight loss should not be extrapolated to approved oral GLP-1 products. Liver-enzyme rates were described as class-like overall, but the single DILI-like event still closed the program.
Related NovaPharma coverage
- Novo Nordisk CagriSema Phase 3 obesity update
- Eli Lilly raises 2026 guidance on Mounjaro demand
- Pfizer company profile
Frequently Asked Questions
Did danuglipron meet its Phase 2b obesity endpoint?
Yes. Pfizer’s Phase 2b trial (NCT04707313) of twice-daily oral danuglipron in adults with obesity without type 2 diabetes showed placebo-adjusted mean weight reductions of about 8% to 13% at 32 weeks and 5% to 9.5% at 26 weeks.
Will Danuglipron Phase 3 studies proceed?
No. In December 2023 Pfizer said the twice-daily formulation will not advance into Phase 3. On April 14, 2025, Pfizer discontinued all danuglipron development after a potential drug-induced liver injury case and regulator input.
What tolerability issues appeared in Phase 2b?
Gastrointestinal adverse events were common: nausea up to 73%, vomiting up to 47%, and diarrhea up to 25%. Discontinuation exceeded 50% across danuglipron doses versus about 40% on placebo.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for danuglipron.
Unlock full calendar →Pfizer pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
Deeper reading
Industry reports & whitepapers
- Lilly's Weight-Loss Pill Approved, Sparking Competition with Novo Nordisk — Eli Lilly's daily weight-loss pill received FDA approval, setting the stage for a competitive battle…
- Ensuring Compatibility for GLP-1-based Drugs — The rise of GLP-1 agonists like Semaglutide demands innovative ready-to-use cartridges to enhance de…